Metformin, the AMPK activator, proved to be effective in meditating vascular protection against calcification, improving myocardial infarction and attenuating ventricular hypertrophy, all of which required the mechanism of AMPK-dependent eNOS activation [26,29,42,43]. This evidence concerns the gene PRKAA1 and myocardial infarction.